rs324013 — STAT6

STAT6 rs324013 — The Promoter Switch That Silences Your Antiviral Guard

STAT6 (Signal Transducer and Activator of Transcription 6)¹¹ STAT6 (Signal Transducer and Activator of Transcription 6)
The central transcription factor activated by IL-4 and IL-13 signaling; when phosphorylated, it dimerizes, enters the nucleus, and switches on genes for IgE production, eosinophil recruitment, and Th2 cell differentiation — the molecular signature of allergic disease orchestrates the body's allergy response from a strategic position in the immune signaling hierarchy. The rs324013 variant sits in the promoter region of the STAT6 gene on chromosome 12q13 — approximately 7 kilobases upstream of the well-studied intron 2 variants rs167769 and rs324011. Where those intronic variants alter an NF-κB binding site and upregulate STAT6 transcription, rs324013 influences a separate regulatory element immediately controlling how much STAT6 the cell makes in the first place.

The Mechanism

The STAT6 promoter is the master on/off switch for Th2 immune programming. Variants in this region change transcription factor binding affinity at the promoter, altering baseline STAT6 expression and the cell's sensitivity to IL-4 and IL-13 signals. He et al. 2008²² He et al. 2008
Genes & Immunity; electrophoretic mobility shift assay (EMSA) in PHA-stimulated PBMCs showed differential transcription factor binding between the C and T alleles at rs324013, confirming functional regulatory activity at this locus.

The T allele's most clinically significant consequence is suppression of IFN-γ (interferon gamma³³ interferon gamma
the primary antiviral cytokine produced by Th1 cells and NK cells; IFN-γ activates macrophages and dendritic cells to clear viral infections and suppresses Th2 polarization — its reduction tilts the immune balance toward allergic over antiviral responses) production in response to herpes simplex virus exposure. When the rs167769-C allele and rs324013-T allele occur on the same chromosome — forming the 6.87-kb "CT haplotype" in the STAT6 promoter region — the result is a cell that overproduces STAT6-driven Th2 cytokines while simultaneously underproducing the IFN-γ needed to suppress HSV replication in the skin.

The Evidence

The primary evidence for rs324013's clinical significance comes from a 2011 study by Howell et al.⁴⁴ Howell et al.
J Allergy Clin Immunol 2011; 444 white atopic dermatitis patients from the ADRN consortium; 10 STAT6 SNPs genotyped across the 12q13 locus investigating why some patients with atopic dermatitis (AD) develop disseminated HSV skin infections — eczema herpeticum (EH) — while others do not. The rs167769-C / rs324013-T two-SNP haplotype spanning the STAT6 promoter region was present in 24.9% of ADEH+ patients but only 9.2% of ADEH− controls (OR 3.33, 95% CI 1.39–8.55, P = 5.17×10⁻⁶). Carriers of the T allele at rs324013 showed significantly reduced IFN-γ production when their peripheral blood mononuclear cells were stimulated with HSV.

A parallel strand of evidence comes from immune defense against parasitic infection. He et al. 2008⁵⁵ He et al. 2008
Genes Immun; 841 subjects in two Mali villages with endemic Schistosoma haematobium; rs324013 associated with higher infection burden (P=0.04); additive interaction with IL13 promoter SNP rs1800925 (P=0.011) found that C/T heterozygotes at rs324013 carried higher parasite loads than CC or TT homozygotes, and the combination of rs324013 CT with the high-IL-13 rs1800925 genotype was particularly detrimental. The EMSA data from this study confirm that both alleles bind transcription factors differently, consistent with a functional regulatory role.

The broader STAT6 promoter-region haplotype block provides strong contextual support. Weidinger et al. 2004⁶⁶ Weidinger et al. 2004
J Med Genet; 1,407 German adults; STAT6 risk haplotype OR 1.7 for IgE ≥100 kU/L and OR 2.54 for 90th-percentile IgE established that variants in this region collectively drive elevated serum IgE. The rs324013 promoter variant is part of this same functional block — its T allele co-segregates with the intronic T alleles at rs167769 and rs324011 in the risk haplotype that elevates Th2 tone across multiple allergic phenotypes.

Practical Actions

Carriers of the T allele — particularly TT homozygotes — face two compounding risks: an amplified Th2 immune tone that drives IgE production and allergic sensitization, and a blunted IFN-γ response to herpes simplex virus. For atopic dermatitis patients, this translates to heightened vigilance for early HSV skin involvement and awareness of triggers that simultaneously suppress antiviral immunity (topical corticosteroids, calcineurin inhibitors applied during active flares). For allergy management, the mechanistic target here is the IL-4/IL-13 → STAT6 axis, which is directly addressed by dupilumab (an anti-IL-4Rα antibody) and, through dietary means, by long-chain omega-3 fatty acids that dampen Th2 polarization.

Interactions

rs324013 operates within a 6.87-kb STAT6 promoter haplotype block that also contains rs167769 (intron 2). The two-SNP haplotype rs167769-C / rs324013-T is the primary risk unit for eczema herpeticum, suggesting these two variants interact functionally to suppress antiviral IFN-γ response in ways that neither achieves alone. Both variants are in linkage disequilibrium with rs324011, the best-characterized STAT6 regulatory SNP that creates a functional NF-κB binding site. Separately, rs324013 shows an additive interaction with the IL13 promoter variant rs1800925 — when both the STAT6 promoter (rs324013 CT) and IL13 promoter (rs1800925 high-IL-13 genotype) are co-inherited, Th2 signaling amplification is substantially greater than either variant alone, a pattern consistent with the IL-13 → STAT6 feed-forward loop that sustains allergic inflammation.